Response to: Assessing the risk of bias and publication bias should be integral parts of the systematic review

Eur J Cancer. 2019 Sep:118:189. doi: 10.1016/j.ejca.2019.05.026. Epub 2019 Jul 2.

Authors

Mairéad Geraldine McNamara¹, Eitan Amir²

Affiliations

¹ Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, M20 4BX, UK; Division of Cancer Sciences, University of Manchester, Manchester, M20 4BX, UK. Electronic address: Mairead.McNamara@christie.nhs.uk.
² Department of Medical Oncology, Princess Margaret Cancer Centre/University of Toronto, 610 University Avenue, Toronto, Ontario, M5G 2M9, Canada.

PMID: 31277809
DOI: 10.1016/j.ejca.2019.05.026

No abstract available

Publication types

Letter
Comment

MeSH terms

Bias
Carcinoma, Hepatocellular*
Child
Humans
Liver Neoplasms*
Publication Bias
Sorafenib

Substances

Sorafenib